Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Is GSK plc Building on Recent Gains?

Daily Change:-42.00p (down 2.14%) as of the latest session

Ishan Mudgal | 10 August 2026

Is Haleon plc Building on Recent Gains?

Daily Change:-3.80p (down 1.03%) as of the latest session

Ishan Mudgal | 10 August 2026

Is Hikma Pharmaceuticals PLC Building on Recent Gains?

Daily Change:-14.00p (down 0.83%) as of the latest session

Ishan Mudgal | 10 August 2026

Is Oxford Biomedica plc Building on Recent Gains?

Daily Change:-9.30p (down 1.84%) as of the latest session

Ishan Mudgal | 10 August 2026

Is AstraZeneca PLC Building on Recent Gains?

Daily Change:+0.03p (up 0.02%) as of the latest session

Ishan Mudgal | 10 August 2026

Applied Nutrition Upgrades Guidance and Buys US Factory as North American Push Accelerates

Applied Nutrition plc (LSE:APN), the Liverpool-headquartered maker of protein powders, pre-workout supplements and diet gummies, has told investors it now expects to beat its own full-year revenue guidance, while agreeing to buy aManufacturingFacilityin upstate New York. The announcement, made on 1 June 2026, bundled …

Ankur Sharma | 10 August 2026

OXB Signs Record 17 New Clients but Cuts 2026 Revenue Guidance by £40m

Oxford Biomedica (LSE:OXB), the Oxford-based contract development andManufacturingorganisation (CDMO) known to the market as OXB, delivered a mixed message to investors on 7 August 2026. A half-year trading update showed the business signing new clients at its fastest pace on record, yet also confirmed …

Ankur Sharma | 10 August 2026

PureTech's Celea Raises $180m and Doses First Phase 3 Patient in IPF Trial

PureTech Health (LSE:PRTC), the London-listed biotech known for founding and spinning out drug-discovery companies, has reached one of the most consequential moments in its history. Celea Therapeutics, the company PureTech created to develop deupirfenidone for idiopathic pulmonary fibrosis (IPF), has completed a $180 million …

Ankur Sharma | 10 August 2026

Tristel Posts Double-Digit Growth and Launches 3T Pro as Digital Push Begins

Tristel plc (LSE:TSTL), the Cambridgeshire-based maker of chlorine dioxide disinfection products for endoscopes, ultrasound probes and other medical devices, has told shareholders it delivered another year of double-digit growth in the twelve months to 30 June 2026. A trading update released on 22 July …

Ankur Sharma | 10 August 2026

Allergy Therapeutics Unveils Positive Peanut and Grass Data as It Bets on a Reset for Allergy Shots

Allergy Therapeutics (LSE:AGY), the Worthing-based maker of injectable allergy immunotherapies, has had an eventful year. Since December 2025 the AIM-listed group has reported clinical progress in both flagship allergen programmes, secured its first grass pollen product approval under Germany's dedicated regulatory pathway, and overhauled …

Ankur Sharma | 10 August 2026
Support

Hi! How can we help you today?

Loading…